Optimization and sustainability assessment of a continuous flow Ru-catalyzed ester hydrogenation for an important precursor of a beta 2-adrenergic receptor agonist

The development of a ruthenium-catalyzed continuous flow ester hydrogenation using hydrogen (H-2) gas is reported. The reaction was utilized for the reduction of an important precursor in the synthesis of abediterol, a beta(2)-adrenoceptor agonist that has undergone phase IIa clinical trials for the treatment of asthma and chronic obstructive pulmonary disorder. The reaction was investigated within a batch autoclave by using a design of experiments (DoE) approach to identify important parameter effects. The optimized flow process was successfully operated over 6 h with inline benchtop(19)F NMR spectroscopy for reaction monitoring. The protocol is shown to be high yielding (98% yield, 3.7 g h(-1)) with very low catalyst loading (0.065 mol%). The environmental impact of the Ru-catalyzed hydrogenation was assessed and compared to an existing stoichiometric lithium aluminum hydride (LAH) reduction and sodium borohydride (NaBH4) reduction. The process mass intensity (PMI) for the Ru-catalyzed hydrogenation (14) compared favorably to a LAH reduction (52) and NaBH(4)reduction (133).